Targeting the IL-17/IL-23 axis in chronic inflammatory immune-mediated diseases

Tsoukas, A., Goodyear, C. S. and McInnes, I. B. (2015) Targeting the IL-17/IL-23 axis in chronic inflammatory immune-mediated diseases. In: Alt, F. W., Honjo, T., Radbruch, A. and Reth, M. (eds.) Molecular Biology of B Cells. Elsevier, pp. 527-539. ISBN 9780123979339 (doi: 10.1016/B978-0-12-397933-9.00028-X)

Abstract

The advent of a variety of cytokine inhibitors in the treatment of autoimmune and autoinflammatory diseases has transformed the clinical outlook in recent years. However, a proportion of patients either does not respond or exhibits only partial or short-lived benefits. As such, there remains intense interest in identifying new pathways that can yield therapeutic benefit when modulated. The IL-17 pathway has been identified in murine models as a potent driver of autoimmune phenomena. IL-17 family cytokines are released by a several leukocyte subsets, primarily T cells and innate lymphocytes. In turn, this family is induced by a variety of upstream cytokines, including IL-23. Several clinical trials have now identified marked benefits upon inhibition of the IL-17/IL-23 axis, particularly in psoriasis. Such data are being extended in a variety of clinical inflammatory diseases with variable benefit arising, including potential deficit. It is likely that agents that target IL-17 and IL-23 will find a place in the management of psoriasis initially with other disease states emerging over time.

• Item Type: Book Sections
• Status: Published
• Glasgow Author(s) Enlighten ID: McInnes, Professor Iain
• Authors: Tsoukas, A., Goodyear, C. S., and McInnes, I. B.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Publisher: Elsevier
• ISBN: 9780123979339